Hypothyroidism in multiple sclerosis patient during fingolimod treatment

J Neurol Sci. 2015 Jan 15;348(1-2):272-3. doi: 10.1016/j.jns.2014.11.008. Epub 2014 Nov 13.

Authors

J Flores¹, Y Rito², G Torres¹, H Jung³, I Treviño-Frenk¹, T Corona¹

Affiliations

¹ Laboratory of Clinical Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
² Laboratory of Clinical Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery, Mexico City, Mexico. Electronic address: yamelrito@yahoo.com.
³ Laboratory of Neuropharmacology, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.

PMID: 25491264
DOI: 10.1016/j.jns.2014.11.008

No abstract available

Keywords: Fingolimod; Hypothyroidism; Multiple sclerosis; Sphingosine-1-phosphate.

Publication types

Case Reports
Letter

MeSH terms

Adult
Female
Fingolimod Hydrochloride / administration & dosage
Fingolimod Hydrochloride / adverse effects*
Humans
Hypothyroidism / chemically induced*
Immunosuppressive Agents / administration & dosage
Immunosuppressive Agents / adverse effects*
Multiple Sclerosis, Relapsing-Remitting / drug therapy*
Young Adult

Substances

Immunosuppressive Agents
Fingolimod Hydrochloride